Most Traveled People Summit 2025: A Gathering of the World's Most Adventurous Travelers in Addis Ababa, Ethiopia in November 2025
8.5.2025 11:00:00 EEST | Business Wire | Press release
The Most Traveled People (MTP) community is thrilled to announce the MTP Summit 2025, set to take place in the fascinating city of Addis Ababa, Ethiopia from 13 to 16 November 2025. This highly anticipated event, supported by the Ethiopian Ministry of Tourism, will bring together the world's most experienced travelers, offering a unique platform for networking, learning, and exploring. The event will take place in the Sheraton Addis, one of Africa’s most prestigious hotels, combining modern luxury with traditional Ethiopian influence.
MTP is the largest extreme travel community in the world, with over 40,000 members who aspire to explore every region in the world. The platform also serves as a system of record for collectors of the world's best countries, regions and World Heritage Sites, as well as restaurants, beaches, hotels, golf courses, and more. MTP connects like-minded adventurers, making travel planning easier and more enriching.
The MTP Summit 2025 promises an impressive lineup of activities and speakers:
- Masterclass Sessions: During the Summit, attendees will benefit from masterclass-level insights delivered by ten renowned speakers, covering topics from assessing risk around you to extreme travel.
- Networking Opportunities: Meet and connect with some of the world's most traveled individuals, sharing experiences and tips.
- Curated Cultural Experiences: Participate in exclusive experiences organized by MTP, exploring the rich culture and history of Ethiopia. MTP will be organizing side trips before, around and after the Summit for participants to get to know one another, network and explore the surrounding areas.
Featured speakers include the following inspirational adventurers, with more to be announced:
- Amos Nachoum: A world-renowned underwater photographer and founder of Big Animals Expeditions. Amos's award-winning work has been featured in National Geographic and BBC Wildlife Photographer of the Year, inspiring a deep connection with the ocean.
- Hayley Kennedy: The first known disabled woman to visit all 193 United Nations member states. Hayley will share stories from her journey around the world and insights on making travel more accessible.
- Johnny Ward: A travel entrepreneur and blogger who turned his passion for travel into a multimillion-dollar business. Johnny will discuss pushing boundaries in extreme travel and lifestyle design.
Charles Veley, Founder and Chairman of MTP, commented:
"We’re thrilled to be hosting this year’s MTP Summit in Ethiopia, a land of rich history with stunning landscapes and vibrant cultures. The event promises to be a platform for learning, connection, and inspiration for inquisitive travelers from around the globe.
“We are delighted to receive the support of the Ethiopian Ministry of Tourism and eagerly anticipate welcoming passionate travelers, sharing stories of exploration, and celebrating the incredible experiences that have shaped our journeys. Together, we will inspire one another to continue discovering the wonders of our world.”
For more information and to register, visit the MTP Summit 2025 Website: https://mtp.travel/mtp-summit-2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250508700552/en/
Contacts
Justyna Janawa, Head of Operations
Phone: +48 603 675 638
Email: contact@mtp.travel
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom